

signals that profoundly affect DC functions towards CD4⁺ CD25⁺ Treg cells. Because NK cell functions are regulated by the balance between inhibitory and activating signals, any future clarification of the role of other NK inhibitory and activating receptors in DC modulation and Treg cell activation will be of great interest.

The cross-presentation of self-antigens by major histocompatibility complex (MHC) class II pathways constitutes an important step towards generating and/or expanding peripheral Treg cells.³⁰ However, we initially settled our experimental design by using DCs and Treg cells from different donors, and DCs encountered CD4⁺ T cells in an 'antigen-free' condition. Therefore, Treg cells induced by NK/NH-primed DCs are generated independently of MHC class II-mediated self-antigen recognition. These results give rise to the possibility that the cross-talk of NK cells, DCs and hepatocytes represents an alternative pathway in the generation and expansion of peripheral Treg cells. However, it should be noted that these results may not apply to all donors because of the complexity of the allogeneic system and the relatively few donors tested.

PD-1-mediated suppressive activities were characteristic for CD4⁺ CD25⁺ Treg cells generated by NH/IL-2 NK-primed DCs. By contrast, natural CD4⁺ CD25⁺ Treg cells exerted their suppressive function, at least in part, in a CTLA-4-dependent fashion. Recent reports have clarified the existence of two subtypes of Treg cells: natural and inducible CD4⁺ CD25⁺ Treg cells. Inducible Treg cells exert suppressive activities by using molecular mechanisms distinct from those of natural regulatory cells.³¹ Our findings further identify the novel pathways by which inducible CD4⁺ CD25⁺ Treg cell activities triggered by NKG2A inhibitory signals are dependent on PD-1-mediated negative costimulation. A recent report identified the interaction of B7 on effector T cells with costimulatory molecules CD28/CTLA-4 on CD4⁺ CD25⁺ Treg cells as molecular mechanisms of their suppressor activity.³² Thus, it is possible that reverse signalling of PDL-1 on effector cells may also be crucial for the negative costimulator-mediated suppressive action of CD4⁺ CD25⁺ Treg cells. In the present study, we did not address the mechanisms by which NH/IL-2 NK-primed DCs induce CD4⁺ CD25⁺ Treg cells with PD-1-dependent suppressive functions. Further study will be needed to clarify this issue.

We previously showed that NKG2A is expressed at higher levels from NK cells isolated from peripheral blood in patients with chronic hepatitis C virus (HCV) infection than from those in healthy donors.²⁰ HCV frequently persists in humans, at least in part, due to inefficient induction of NK activity as well as specific T cell responses.³³⁻³⁵ The small percentage of patients who spontaneously clear the virus and recover from chronic hepatitis C mount vigorous HCV-specific CD4⁺ and CD8⁺ T cell responses.^{36,37} Research has described an increased frequency of CD4⁺

CD25⁺ T cells in the blood of patients with persistent HCV infection compared with those who have spontaneously cleared HCV.^{38,39} Our current findings raise the interesting possibility that increased NKG2A expression on NK cells may lead to DC-mediated induction of Treg cells, leading to the inhibition of adaptive responses to HCV and failure to eliminate this virus. Indeed, CD4⁺ CD25⁺ T cells induced by HCV-NK/Hep3B hepatoma cell-primed DCs expressed and suppressed effector T cell functions at greater levels than those induced by N-NK/Hep3B-primed DCs (our unpublished data). Interestingly, a recent study identified PD-1-mediated signals as a critical pathway to induce anergic CD8⁺ T cells and impair antiviral CTL responses in chronic viral infection.⁴⁰ In this regard, the therapeutic modification of the PD-1 pathway may synergistically augment antiviral immunity by suppressing Treg activity and recovering CTL responses. It is important to establish whether the PD-1 pathway in liver lymphocytes may be operable *in vivo* and play a critical role in suppression of virus-specific immunity in HCV infection.

In conclusion, we have demonstrated that interaction of NK cells and hepatic cells via NKG2A leads to DC induction of CD4⁺ CD25⁺ T cells with PD-1-dependent regulatory activities. These findings also imply that NK receptor signals of NK cells may dictate DC-mediated adaptive immune responses towards tolerogenic or immunogenic status via induction of Treg cells.

Acknowledgements

This work was supported by a grant-in-aid from the Ministry of Culture, Sports, Science and Technology of Japan and a grant-in-aid for research on hepatitis and BSE from the Ministry of Health, Labour and Welfare of Japan. It was also partially supported by the 21st Century Centre of Excellence Programme of the Ministry of Education, Culture, Sports, Science and Technology of Japan.

References

- 1 Shevach EM. CD4⁺ CD25⁺ suppressor T cells: more questions than answers. *Nat Rev Immunol* 2002; 2:389-400.
- 2 Jonuleit H, Schmitt E, Stassen M, Tuetttenberg A, Knop J, Enk AH. Identification of functional characterization of human CD4⁺ CD25⁺ T cells with regulatory properties isolated from peripheral blood. *J Exp Med* 2001; 193:1285-94.
- 3 Dieckmann D, Plottner H, Berchtold S, Berger T, Schuler G. *Ex vivo* isolation and characterization of CD4⁺ CD25⁺ T cells with regulatory properties from human blood. *J Exp Med* 2001; 193:1303-10.
- 4 Belkaid Y, Piccirillo CA, Mendez S, Shevach EM, Sacks DL. CD4⁺ CD25⁺ regulatory T cells control *Leishmania* major persistence and immunity. *Nature* 2002; 420:502-7.
- 5 Wang HY, Lee DA, Peng G, Guo Z, Li Y, Kuniwa Y, Shevach EM, Wang RF. Tumour-specific human CD4⁺ regulatory T cells

- and their ligands: implication for immunotherapy. *Immunity* 2004; 20:107–18.
- 6 Read S, Malmstrom V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD4⁺ CD25⁺ regulatory cells that control intestinal inflammation. *J Exp Med* 2002; 192:295–302.
 - 7 Herman AE, Freeman GJ, Mathis D, Benoist C. CD4⁺ CD25⁺ T regulatory cells dependent on ICOS promote regulation of effector cells in the prediabetic lesion. *J Exp Med* 2004; 199:1479–89.
 - 8 Houry SJ, Sayegh MH. The roles of the new negative T cell costimulatory pathways in regulating autoimmunity. *Immunity* 2004; 20:529–38.
 - 9 Gavin MA, Clarke SR, Negrou E, Gallegos A, Rudensky A. Homeostasis and anergy of CD4⁺ CD25⁺ suppressor T cells *in vivo*. *Nat Immunol* 2004; 3:33–41.
 - 10 Steinman RM, Hawiger D, Nussenzweig D. Tolerogenic dendritic cells. *Annu Rev Immunol* 2003; 21:685–711.
 - 11 Mahnke K, Quan Y, Knop J, Enk AH. Induction of CD4⁺ CD25⁺ regulatory T cells by targeting of antigens to immature dendritic cells. *Blood* 2003; 101:4862–9.
 - 12 Annacker O, Pimenta-Araujo R, Burlen-Defranoux O, Barbosa TC, Cumano A, Bandeira A. CD4⁺ CD25⁺ T cells regulate the expansion of peripheral CD4⁺ T cells through the production of IL-10. *J Immunol* 2001; 166:3008–18.
 - 13 Yamagiwa S, Gray JD, Hashimoto H, Horwitz DA. A role of TGF- β in the generation and expansion of CD4⁺ CD25⁺ regulatory T cells from human peripheral blood. *J Immunol* 2001; 166:7282–9.
 - 14 Peng Y, Laouar Y, Li MO, Green EA, Flavell RA. TGF- β regulates *in vivo* expansion of Foxp3-expressing CD4⁺ CD25⁺ regulatory T cells responsible for protection against diabetes. *Proc Natl Acad Sci USA* 2004; 101:4572–7.
 - 15 Moretta A. The dialogue between human natural killer cells and dendritic cells. *Curr Opin Immunol* 2005; 17:306–11.
 - 16 Walzer T, Dalod M, Robbins SH, Zitvogel L, Vivier E. Natural killer cells and dendritic cells: 'L'union fait la force'. *Blood* 2005; 106:2252–8.
 - 17 Mocikat R, Braumuller H, Gumy A *et al.* Natural killer cells activated by MHC^{LOW} targets prime dendritic cells to induce protective CD8 T cell responses. *Immunity* 2003; 19:561–9.
 - 18 Van den Broeke LT, Daschbach E, Thomas EK, Andringa G, Berzofsky JA. Dendritic cell-induced activation of adaptive and innate antitumour immunity. *J Immunol* 2003; 171:5842–52.
 - 19 Cerwenka A, Lanier LL. Natural killer cells, viruses and cancer. *Nat Rev Immunol* 2001; 1:41–9.
 - 20 Jinushi M, Takehara T, Tatsumi T *et al.* Negative regulation of NK cell activities by inhibitory receptor CD94/NKG2A leads to the altered NK cell-induced modulation of dendritic cell functions in chronic hepatitis C virus infection. *J Immunol* 2004; 173:6072–81.
 - 21 Lee N, Goodlett DR, Ishitani A, Marquardt H, Geraghty DE. HLA-E surface expression depends on binding of TAP-dependent peptides derived from certain HLA class I signal sequences. *J Immunol* 1998; 160:4951–60.
 - 22 Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, Spies T. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. *Science* 1999; 285:727–9.
 - 23 Pende D, Sivori S, Accame L *et al.* HLA-G recognition by human natural killer cells. Involvement of CD94 both as inhibitory and as activating receptor complex. *Eur J Immunol* 1997; 27:1875–80.
 - 24 Valerie V, Vosters O, Beuneu C, Nicaise C, Stordeur P, Goldman M. Induction of FOXP3-expressing regulatory CD4⁺ T cells by human mature autologous dendritic cells. *Eur J Immunol* 2003; 34:762–72.
 - 25 Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S. Stimulation of CD4⁺ CD25⁺ regulatory T cells through GITR break immunological self-tolerance. *Nat Immunol* 2002; 3:135–42.
 - 26 Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. *Science* 2003; 299:1057–61.
 - 27 Piccioli D, Sbrana S, Melandri E, Valiante NM. Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. *J Exp Med* 2002; 195:335–41.
 - 28 Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA, Mauri C. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNF- α therapy. *J Exp Med* 2004; 200:277–85.
 - 29 Wu AJ, Hua H, Munson SH, McDevitt HO. Tumour necrosis factor- α regulation of CD4⁺ CD25⁺ T cell levels in NOD mice. *Proc Natl Acad Sci USA* 2002; 99:12287–92.
 - 30 Kretschmer K, Apostolou I, Hawiger D, Khazaie K, Nussenzweig MC, von Boehmer H. Inducing and expanding regulatory T cell populations by foreign antigen. *Nat Immunol* 2005; 6:1219–27.
 - 31 Bluestone JA, Abbas AK. Natural and adaptive regulatory T cells. *Nat Rev Immunol* 2003; 3:253–7.
 - 32 Paust S, Lu L, McCarty N, Cantor H. Engagement of B7 on effector T cells by regulatory T cells prevents autoimmune disease. *Proc Natl Acad Sci USA* 2004; 101:10398–403.
 - 33 Ahmad A, Alvarez F. Role of NK and NKT cells in the immunopathogenesis of HCV-induced hepatitis. *J Leukoc Biol* 2004; 76:743–59.
 - 34 Golden-Mason L, Rosen HR. Natural killer cells: primary target for hepatitis C virus immune evasion strategies. *Liver Transplant* 2006; 12:363–72.
 - 35 Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. *Nat Rev Immunol* 2005; 5:215–29.
 - 36 Lauer GM, Barnes E, Lucas M *et al.* High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. *Gastroenterology* 2004; 127:924–36.
 - 37 Cox AL, Mosbruger T, Lauer GM, Pardoll D, Thomas DL, Ray S. Comprehensive analysis of CD8⁺ T cell responses during longitudinal study of acute human hepatitis C. *Hepatology* 2005; 42:104–12.
 - 38 Cabrera R, Tu Z, Xu Y, Firpi RJ, Rosen HR, Liu C, Nelson DR. An immunomodulatory role for CD4⁺ CD25⁺ regulatory T lymphocytes in hepatitis C virus infection. *Hepatology* 2004; 40:1062–71.
 - 39 Rushbrook SM, Ward SM, Unitt E, Vowler M, Lucas M, Kleneman P, Alexander GJ. Regulatory T cells suppress *in vitro* proliferation of virus-specific CD8⁺ T cells during persistent hepatitis C virus infection. *J Virol* 2005; 79:7852–9.
 - 40 Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Freeman GJ, Ahmed R. Restoring function in exhausted CD8 T cells during chronic viral infection. *Nature* 2006; 439:682–7.

Editor-Communicated Paper

Tandem Repeats of Lactoferrin-Derived Anti-Hepatitis C Virus Peptide Enhance Antiviral Activity in Cultured Human Hepatocytes

Ken-ichi Abe^{1,a}, Akito Nozaki^{1,a}, Kazushi Tamura², Masanori Ikeda¹, Kazuhito Naka¹, Hiromichi Dansako¹, Hiro-o Hoshino², Katsuaki Tanaka³, and Nobuyuki Kato^{*,1}

¹Department of Molecular Biology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Okayama 700–8558, Japan, ²Department of Virology and Preventive Medicine, Gunma University Graduate School of Medicine, Maebashi, Gunma 371–8511, Japan, and ³Gastroenterological Center, Yokohama City University of Medical Center, Yokohama, Kanagawa 236–0004, Japan

Communicated by Dr. Masanobu Ohuchi: Received November 8, 2006. Accepted November 13, 2006

Abstract: Previously, we found that bovine and human lactoferrin (LF) specifically inhibited hepatitis C virus (HCV) infection in cultured non-neoplastic human hepatocyte-derived PH5CH8 cells, and we identified 33 amino acid residues (termed C-s3-33; amino acid 600–632) from human LF that were primarily responsible for the binding activity to the HCV E2 envelope protein and for the inhibiting activity against HCV infection. Since the anti-HCV activity of C-s3-33 was weaker than that of human LF, we speculated that an increase of E2 protein-binding activity might contribute to the enhancement of anti-HCV activity. To test this possibility, we made two repeats [(C-s3-33)₂] and three repeats [(C-s3-33)₃] of C-s3-33 and characterized them. Far-Western blot analysis revealed that the E2 protein-binding activities of (C-s3-33)₂ and (C-s3-33)₃ became stronger than that of the C-s3-33, and that the binding activity of (C-s3-33)₃ was stronger than that of (C-s3-33)₂. Using an HCV infection system in PH5CH8 cells, we demonstrated that the anti-HCV activities of (C-s3-33)₂ and (C-s3-33)₃ became stronger than that of the C-s3-33. Furthermore, using a recently developed infection system with a VSV pseudotype harboring the green fluorescent protein gene and the native E1 and E2 genes, we demonstrated that the antiviral activities of (C-s3-33)₂ and (C-s3-33)₃ were stronger than that of C-s3-33. These results suggest that tandem repeats of LF-derived anti-HCV peptide are useful as anti-HCV reagents.

Key words: Hepatitis C virus, Lactoferrin, Anti-HCV peptide, E2 protein-binding activity

Hepatitis C virus (HCV) infection frequently causes chronic hepatitis, which progresses to liver cirrhosis and hepatocellular carcinoma (28). HCV is an enveloped positive single-stranded RNA (9.6 kb) virus belonging to the *Flaviviridae*. The HCV genome encodes a large polyprotein precursor of about 3,000 amino acids (aa), which is cleaved by the host and viral proteases into at least 10 proteins: the core, envelope 1 (E1), E2, p7, and non-structural 2 (NS2), NS3, NS4A, NS4B, NS5A, and NS5B (7, 8, 18). These HCV proteins function not only in virus replication but may also

affect a variety of cellular functions, including gene expression, signal transduction, and apoptosis (1, 17).

Approximately 170 million people worldwide are infected with HCV (32). The combination of a pegylated interferon with ribavirin is the current standard therapy for chronic hepatitis C and yields a sustained virological response rate of about 55% (6). This means that about 45% of patients with chronic hepatitis C are still threatened by the progress of the disease to cirrhosis and hepatocellular carcinoma.

Although the entry mechanism of HCV remains unclear, to date, several candidates for HCV receptors

*Address correspondence to Dr. Nobuyuki Kato, Department of Molecular Biology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2–5–1 Shikata-cho, Okayama, Okayama 700–8558, Japan. Fax: +81–86–235–7392. E-mail: nkato@md.okayama-u.ac.jp

^aBoth authors contributed equally to this work.

Abbreviations: aa, amino acids; DMEM, Dulbecco's modified Eagle's medium; E2, envelope 2; GFP, green fluorescent protein; HCV, hepatitis C virus; LF, lactoferrin; MBP, maltose-binding protein; NS2, non-structural 2; TF, transferrin; VSV, vesicular stomatitis virus.

have been reported: CD81, the scavenger receptor class B type I, the mannose-binding lectins DC-SIGN and L-SIGN, low-density lipoprotein receptors, etc. (4). Most of them have been identified as interacting materials with a soluble and truncated form of the HCV E2 protein, because of the lack of efficient HCV proliferation in cell cultures, although several culture systems using PCR for detection of HCV infection have been reported (20). However, a major advance in investigating HCV entry has been achieved by the development of pseudotype viruses bearing HCV E1 and E2 proteins assembled onto retrovirus particles (2, 9) or vesicular stomatitis virus (VSV) particles (3, 23, 30). Extensive characterization of the pseudotype viruses has shown that these mimic the early steps of the HCV life cycle. This system has allowed the study of the role of candidate receptors in the early steps of HCV infection (4).

We previously found that bovine and human lactoferrins (LFs) specifically prevented HCV infection in cultured human non-neoplastic hepatocyte PH5CH8 cells using the PCR method for detection of HCV infection (10, 12). Regarding these findings, some clinical studies have demonstrated that monotherapy with bovine LF improves the serum HCV RNA and/or alanine aminotransferase levels in patients with chronic hepatitis C (15, 16, 27, 31).

LF is an 80-kDa mammalian iron-binding glycoprotein and consists of two homologous globular lobes (an N-lobe and a C-lobe), each with a single iron (Fe^{3+}) binding site. It is structurally related to the plasma iron-transport protein transferrin (TF). LF's biological roles include activities in the host defense mechanism as well as in iron metabolism (21, 22). Unlike TF, LF is a primary defense protein against microbial infection. LF possesses strong bacteriostatic and bactericidal activities against pathogenic bacteria, as well as inhibitory activity against pathogenic viruses (5, 21, 22, 33).

LF's preventive mechanism against HCV infection has been thought to be the direct interaction between LF and HCV; indeed, by Far-Western blot analysis using thioredoxin-fused LF fragments expressed in *Escherichia coli* (*E. coli*) and the soluble E2 protein expressed in Chinese hamster ovary cells, we demonstrated that the 93 carboxyl aa of LF (human, bovine, and horse), termed C-s3, specifically bound to the E2 protein (25). On the other hand, Yi et al. (34) independently reported that the E1 and E2 proteins could bind to human and bovine LFs, although the binding region of LF was not identified. Furthermore, we identified the 33 aa of human LF (termed C-s3-33; aa 600–632), which was primarily responsible for the E2 protein-binding activity, and demonstrated that maltose-binding protein (MBP)-fused C-s3-33 prevented HCV infection

in PH5CH8 hepatocyte cells (25). However, the E2 protein-binding activity and the anti-HCV activity of C-s3-33 were obviously weaker than those of human LF. Therefore, we presumed that the increase of the E2 protein-binding activity would lead to the enhancement of anti-HCV activity.

To evaluate this idea, we made tandem repeats of C-s3-33, and compared their E2 protein-binding activities and anti-HCV activities with those of the C-s3-33. Here, we report our findings that the anti-HCV activity of the tandem repeats were stronger than that of the monomer when accompanied by the enhancement of the E2 protein-binding activity, by analyses using not only the HCV infection system but also the infection system of a VSV pseudotype bearing the native forms of HCV E1 and E2 proteins.

Materials and Methods

Cell cultures. Simian virus 40 large T antigen-immortalized non-neoplastic human PH5CH8 hepatocytes were maintained as described previously (11, 24). Human hepatoblastoma HepG2 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum.

Construction of expression plasmids for *E. coli*. The pMAL-c2X (hLF600–632) (25) expression plasmid for the MBP-fused C-s3-33 LF fragment, was used as a template for the PCR using a primer set of hLFB6 5'-TGATAGGATCCGTGGTGTCTCGGATGATAAGG-3' containing the *Bam*HI recognition site (underlined) (25) and 632R6A 5'-ATCCATCCGAGACACCA-CAAACTTGTCCGGGCAGTCAGATCC-3' containing an extra 18 nts (underlined) encoding the amino-terminal 6 aa of the C-s3-33 LF fragment. After PCR (20 cycles) using KOD-plus DNA polymerase (Toyobo, Osaka, Japan), the amplified PCR product was used as a template for a second PCR using the primer set of hLFB6 and 632R 5'-TAATAAAGCTTT-TAAACTTGTCCGGGCAGTCAGATCC-3' containing the *Hind*III recognition site (underlined) (25). After PCR (35 cycles) using KOD-plus DNA polymerase, amplified PCR products (approximately 200 bp for the two-repeat form and approximately 300 bp for the three-repeat form) were subcloned into the *Bam*HI and *Hind*III sites of pMAL-c2X, and were used as expression plasmids for the production of the MBP-fused (C-s3-33)₂ and (C-s3-33)₃.

To prepare an expression plasmid for the production of the MBP-fused C-s3-33-relevant fragment (aa 587–619) of human TF, pCXbsr/huTF (29) encoding full-length human TF was used as a template for the PCR using a primer set of hTF587F 5'-TGATAG-

GATCCGTGGTCACACGG-3' containing the *Bam*HI recognition site (underlined) and hTF619R 5'-TAATAAAGCTTTTAAAAGTTGCCCG-3' containing the *Hind*III recognition site (underlined). After PCR (35 cycles) using KOD-plus DNA polymerase, the amplified PCR product was subcloned into the *Bam*HI and *Hind*III sites of pMAL-c2X, and was used as the expression plasmid.

Expression and purification of the MBP-fused protein. Expression and purification of the MBP-fused LF fragment [C-s3-33, (C-s3-33)₂, or (C-s3-33)₃] or the MBP-fused C-s3-33-relevant fragment of human TF were carried out as described previously (25). Briefly, the expression plasmid for MBP-fused protein was transformed into the *E. coli* strain JM109. The transformants were cultured at 37 C for several hours, and the harvested cells were sonicated. After removal of insoluble cellular debris by centrifugation, the supernatant obtained as the soluble fraction was applied onto an amylose resin affinity column (New England Biolabs) to obtain the MBP-fused protein. The purity of the obtained MBP-fused protein was evaluated to be more than 95% by electrophoresis on 10% SDS-PAGE gels. The concentration of the purified MBP-fused protein was determined by using Coomassie protein assay reagent (Pierce). The MBP2 (43 kDa) produced from the pMAL-c2X with a stop codon inserted into the *Xmn*I site was used as a control protein.

Far-Western blot analysis. Far-Western blot analysis was carried out as described previously (25). Briefly, 0.5 µg of human LF, MBP2, and MBP-fused LF fragments were resolved by 10% SDS-PAGE and transferred to polyvinylidene difluoride membranes. After blocking with N-buffer (25), a binding reaction was carried out using the secreted form of the E2 protein (E2-681) consisting of aa 384–681 expressed in Chinese hamster ovary cells as a probe (14), and then rat monoclonal antibody, MO-12 (13), against E2 protein was used for the detection of E2 protein-bound MBP-fused LF fragments.

Assay for anti-HCV activity of MBP-fused protein. An assay for anti-HCV activity of the MBP-fused LF fragment was carried out by the method described previously (25). Briefly, 2 µl (2 × 10⁴ HCV) of the HCV-positive serum HCV-O (previously described as 1B-2 (19)) (genotype 1b) and the MBP-fused LF fragment (final concentration, 0.5, 1.0, and 2.0 mg/ml) were pre-incubated for 60 min at 4 C and then inoculated onto the PH5CH8 cells (1.5 × 10⁴ cells were cultured for 2 days before viral inoculation on a 96-well plate). After incubation of the cells for 90 min at 37 C, the cells were washed three times with PBS and further cultured for 1 day at 32 C. Cellular RNA (0.5 µg) prepared by

ISOGEN extraction kit (Nippon Gene Co., Toyama, Japan) was used for the quantitative analysis of HCV RNA using LightCycler PCR as described previously (26). As the positive and negative controls for anti-HCV activity, human LF and MBP2, respectively, were used.

Assay for anti-VSV pseudotype activity of MBP-fused protein. For this assay, the VSV pseudotype VSVΔG*(HCV), bearing the native forms of HCV E1 and E2 proteins from the O strain (19), was used. VSVΔG*(HCV) was prepared by introducing the native form of E1 and E2 proteins into recombinant VSV, VSVΔG*, which harbors the green fluorescent protein (GFP) gene instead of the VSV G envelope protein gene (30). An assay for the anti-VSV pseudotype activity of the MBP-fused LF fragment was carried out by a method described previously (30). Briefly, VSVΔG*(HCV) (Approximately 100 IU/assay) was pre-incubated with the MBP-fused LF fragment (final concentration, 0.1–1.0 mg/ml) at 37 C for 60 min and inoculated onto PH5CH8 or HepG2 cells (1.5 × 10⁴ cells were cultured for 2 days before viral inoculation on a 96-well plate). After incubation of the cells for 90 min at 37 C, the cells were washed with DMEM three times and incubated with fresh culture medium. VSVΔG*G was used as a control in this assay. After 24 hr of incubation, each infectious titer was determined by counting the number of GFP-expressing cells under a fluorescence microscope. As the positive and negative controls for the assay, human LF and MBP2 were used, respectively. Human TF and an MBP-fused C-s3-33-relevant fragment of human TF were also used for the assay.

Results

Two and Three Repeats of the Human LF Fragment (C-s3-33) Strengthened the E2 Protein-Binding Activity

Previously we found that bovine and human LFs prevented HCV infection in PH5CH8 cells via direct interaction between LF and HCV (10, 12), and we further identified 33 aa residues (C-s3-33: aa 600–632 of human LF) as an essential and minimum domain possessing binding activity for the HCV E2 protein (secreted form consisting of aa 384–681) and inhibiting activity against HCV infection (25). This result suggested that the E2 protein-binding activity contributes to the anti-HCV activity. However, the E2 protein-binding activity of C-s3-33 was somewhat weaker than that of human LF (25), and the anti-HCV activity of C-s3-33 (IC₅₀ = 20 µM) in the infection system using PH5CH8 cells was also weaker than that of human LF (IC₅₀ = 5 µM) (25). To improve these points, we first tried to

enhance the E2 protein-binding activity of C-s3-33 by the multiplication of C-s3-33. Initially, we made pMAL-c2X-based expression vectors encoding two, three, and four repeats of C-s3-33 as MBP-fused proteins, and then expressed them in *E. coli*. We successfully purified two repeats (C-s3-33)₂ and three repeats (C-s3-33)₃ of C-s3-33 as soluble forms of the MBP-fused protein; the purification of the four repeats of C-s3-33 failed due to problems with solubility. Using the

MBP-fused C-s3-33, (C-s3-33)₂ and (C-s3-33)₃, we performed Far-Western blot analysis to compare their E2 protein-binding activities. The result revealed that the E2 protein-binding activities of (C-s3-33)₂ and (C-s3-33)₃ became stronger than that of the C-s3-33, and the binding activity of (C-s3-33)₃ was stronger than that of (C-s3-33)₂ (Fig. 1). Although the E2 protein-binding activity of C-s3-33 was weaker than that of human LF, the binding activities of (C-s3-33)₂ and (C-s3-33)₃




Fig. 1. Comparison of the E2 protein-binding activities of MBP-fused C-s3-33, (C-s3-33)₂, and (C-s3-33)₃. MBP-fused C-s3-33, (C-s3-33)₂, and (C-s3-33)₃ (0.5 μ g each) were resolved by 10% SDS-PAGE. Human LF and MBP2 (0.5 μ g each) were also used for the assay as control materials. Far-Western blot analysis using the E2 protein expressed in Chinese hamster ovary cells (14) as a probe was performed as described under 'Materials and Methods'. Rat monoclonal antibody MO-12 (13) against the E2 protein was used for the detection of the E2 protein bound to MBP-fused C-s3-33, (C-s3-33)₂, and (C-s3-33)₃, as well as human LF. Far-Western blot analysis in the absence of the E2 protein was also performed. The bottom panel shows the results for human LF, MBP2, and MBP-fused C-s3-33, (C-s3-33)₂, and (C-s3-33)₃, detected by staining with Coomassie Brilliant Blue.

became comparable with that of human LF (Fig. 1). To exclude the possibility of cross-reactions between C-s3-33 and the anti-E2 antibody, we performed a Far-Western blot analysis in the absence of the E2 protein. No significant bands were obtained in this control experiment (Fig. 1). The Far-Western blot analysis using normal rat serum instead of anti-E2 antibody also detected no significant bands (data not shown). These results suggest that the specific E2 protein-binding activities of (C-s3-33)₂ and (C-s3-33)₃ increase with the degree of multiplication of C-s3-33.

(C-s3-33)₂ and (C-s3-33)₃ Efficiently Prevented HCV Infection in PH5CH8 Cells

Since we obtained the expected results that the E2-binding activities of (C-s3-33)₂ and (C-s3-33)₃ were stronger than that of C-s3-33, we next compared their anti-HCV activities in our HCV infection system using PH5CH8 cells (10, 25). The obtained result (Fig. 2)

revealed that the anti-HCV activities of (C-s3-33)₂ and (C-s3-33)₃ (IC₅₀=10 μM in both) became stronger than that of the C-s3-33 (IC₅₀=23 μM), although their activities were somewhat weaker than that of human LF (IC₅₀=5 μM). These results support the previous suggestion that the E2 protein-binding activity of C-s3-33 contributes to the inhibition of HCV infection (inoculum HCV-O) in human hepatocyte cells (25). However, in our HCV infection system, we failed to clearly show a difference in inhibiting activities between (C-s3-33)₂ and (C-s3-33)₃, because each standard deviation became somewhat large value due to the low level of cell culture-based HCV infection (20, 25, 31). In order to improve this point, we developed an infection system with VSVΔG*(HCV), a VSV pseudotype bearing the native E1 and E2 proteins derived from HCV-O (30), and this VSV pseudotype was used for further analysis as described below.




Fig. 2. Anti-HCV activities of MBP-fused C-s3-33, (C-s3-33)₂, and (C-s3-33)₃ in an HCV infection system using PH5CH8 cells. PH5CH8 cells and the inoculum HCV-O were used for the HCV-inhibiting assay, as described under "Materials and Methods." The number in the ordinate axis indicates the percent of HCV RNA determined by real-time LightCycler PCR (26). Approximately 2,000 copies of HCV RNA per μg of cellular RNA were reproducibly obtained using this HCV infection system (10, 26). In addition to the MBP-fused C-s3-33, (C-s3-33)₂, and (C-s3-33)₃, human LF and MBP2 were also used for the assay as control materials. The data are means ± SD of triplicates from three independent experiments.

Antiviral Effects of (C-s3-33)₂ and (C-s3-33)₃ against VSVΔG(HCV) Infection in PH5CH8 Cells*

Since PH5CH8 cells showed good susceptibility to our developed VSV pseudotype, VSVΔG*(HCV) (30), we examined the antiviral effects of (C-s3-33)₂ and (C-s3-33)₃ against VSVΔG*(HCV) infection in PH5CH8 cells, and compared them with those of the C-s3-33 and human LF. In this experiment, the antiviral effects of human TF and a C-s3-33-relevant fragment of human TF were also examined. The results (Fig. 3) clearly showed that human LF (IC₅₀=0.6 μM) strongly inhibited VSVΔG*(HCV) infection, but that human TF and the C-s3-33-relevant fragment of human TF did not, nor did MBP2, suggesting that inhibition against VSVΔG*(HCV) infection also occurred in an LF-specific manner as observed previously in the HCV infection system (25, 31). These results support previous findings (23, 30) using the VSV pseudotype infection

system. Furthermore, we obtained clear results that C-s3-33 showed inhibiting activity against VSVΔG*(HCV) infection, and that its inhibiting activity was increased with multiplication of C-s3-33. The IC₅₀ doses of C-s3-33, (C-s3-33)₂, and (C-s3-33)₃ were 17 μM, 5.0 μM, and 3.0 μM, respectively. This result indicates that antiviral activity of C-s3-33 is improved by the duplication and triplication of C-s3-33, although the antiviral activity of (C-s3-33)₃ is still weaker than that of human LF. We confirmed that these LF fragments did not inhibit VSVΔG*(control virus without E1 and E2 proteins) infection in PH5CH8 cells (data not shown). In summary, our results suggest that direct interaction of the C-s3-33 fragment with the E2 protein in VSVΔG*(HCV) prevents the virus infection in PH5CH8 cells.




Fig. 3. Antiviral activity of the MBP-fused C-s3-33, (C-s3-33)₂, and (C-s3-33)₃ in the infection system of pseudotype virus using PH5CH8 cells. PH5CH8 cells and the VSV pseudotype, VSVΔG*(HCV), were used for the HCV-inhibiting assay, as described under "Materials and Methods". The number in the ordinate axis indicates the relative infectivity (%) calculated by counting GFP-positive cells. Approximately 100 GFP-positive cells per one assay were reproducibly obtained using this pseudotype infection system (30). In addition to the MBP-fused C-s3-33, (C-s3-33)₂, and (C-s3-33)₃, human LF, human TF, MBP2, and an MBP-fused C-s3-33-relevant fragment of human TF were also used for the assay as controls. The data are means ± SD of three independent experiments.

Antiviral Effects of (C-s3-33)₂ and (C-s3-33)₃ against VSVΔG(HCV) Infection in HepG2 Cells*

We have shown the inhibiting activities of LF fragments against HCV infection or VSV pseudotype infection in PH5CH8 cells; however, it is not clear whether or not the LF fragments used in this study show inhibiting activities against virus infection in cells other than PH5CH8 cells. To clarify this point, HepG2 cells were used for the analysis, because HepG2 cells showed the highest susceptibility to VSVΔG*(HCV) among 25 cell lines examined (30). As a consequence, we obtained similar results (Fig. 4) with those obtained in the infection system using PH5CH8 cells. The IC₃₀ doses of C-s3-33, (C-s3-33)₂, and (C-s3-33)₃ were >12 μM, 7.6 μM, and 3.9 μM, respectively, indicating that, again, the inhibiting activity was increased with multiplication of C-s3-33, although antiviral activity of (C-s3-33)₃ was still weaker than that of human LF (IC₅₀=1.2 μM). In conclusion, our results indicated that tandem repeats of

C-s3-33 enhanced the inhibiting activity in cell culture-based HCV infection.

Discussion

In our previous (30) and present studies, we showed that pretreatment of VSV pseudotypes with bovine and human LFs reduced the infectivity of VSVΔG*(HCV) and VSVΔG*(E2) bearing only the E2 protein in a dose-dependent manner, whereas pretreatment with TF did not. In contrast, LFs partially inhibited the infectivity of VSVΔG*(E1) bearing only the E1 protein (30). These results suggested that the interaction of LF and the E2 protein is the main contributing factor to the prevention of HCV infection. This idea has been strongly supported by the results obtained in this study. We demonstrated that tandem repeats of C-s3-33, an anti-HCV peptide derived from human LF, enhanced the E2 protein-binding activity and the inhibiting activity




Fig. 4. Antiviral activity of the MBP-fused C-s3-33, (C-s3-33)₂, and (C-s3-33)₃ in the infection system of the pseudotype virus using HepG2 cells. HepG2 cells and the VSV pseudotype, VSVΔG*(HCV), were used for the HCV-inhibiting assay, as described in "Materials and Methods". The number in the ordinate axis indicates the relative infectivity (%) calculated by counting GFP-positive cells. Approximately 100 GFP-positive cells per one assay were reproducibly obtained using this pseudotype infection system (30). In addition to the MBP-fused C-s3-33, (C-s3-33)₂, and (C-s3-33)₃, human LF, human TF, and MBP2 were used for the assay as controls. The data are means ± SD of three independent experiments.

against infection by HCV or the VSV pseudotype, VSV Δ G*(HCV), in human hepatic cell lines. These results strongly suggest that the direct interaction between C-s3-33 and the E2 protein plays a central role in the inhibition of HCV infection by LF.

Since C-s3-33 or repeated forms of C-s3-33 could prevent HCV and VSV Δ G*(HCV) infection, C-s3-33 must bind to a region other than the region (aa 441–500 of E2 protein) required for heteromeric complex formation between E1 and E2 proteins. Our preliminary results suggested that the C-s3-33 bound to aa 411–500 and aa 600–661 of the E2 protein, indicating that the target sites of C-s3-33 may be plural. This result suggests a rather complex interaction between C-s3-33 and the E2 protein. To clarify this point, further comprehensive analysis will be needed.

Although tandem repeats of C-s3-33 enhanced the anti-HCV activity compared with that of the C-s3-33, the fact that their antiviral activities were still several-fold weaker than that of original human LF remains a subject to be resolved. As one approach to increase anti-HCV activity, tandem repeats of C-s3-33-relevant fragment of bovine LF may be useful, because we previously observed that the anti-HCV activity of bovine LF (IC_{50} =1.5 μ M) was stronger than that of human LF (IC_{50} =5.0 μ M) (26), and that the E2 protein-binding activity of the C-s3 (93 aa)-relevant fragment of bovine LF was stronger than that of C-s3 (25). Since 10 aa out of 33 aa differ between C-s3-33 and its relevant fragment of bovine LF, some aa substitutions between both fragments may help to further increase the anti-HCV activity of LF-derived peptides. Alternatively, some spacer between the C-s3-33 repeats may be needed. Therefore, further trials will be needed to achieve the maximum anti-HCV activity of C-s3-33.

In conclusion, the results of the present study demonstrated that tandem repeats of human LF-derived 33 aa prevented HCV infection more strongly than the 33 aa, and suggest that this repeated form will be useful as a novel anti-HCV reagent.

We thank T. Nakamura and A. Morishita for their technical assistance. This work was supported by a Grant-in-Aid for the Third-term Comprehensive 10-year Strategy for Cancer Control and by a Grant-in-Aid for research on hepatitis, both from the Ministry of Health, Labour, and Welfare, Japan; and by the Program for the Promotion of Fundamental Studies in Health Science of the Pharmaceutical and Medical Device Agency (PMAD), Japan. K.A. was supported by a Research Fellowship from the Japan Society for the Promotion of Science (JSPS) for Young Scientists.

References

- 1) Bartenschlager, R., and Lohmann, V. 2000. Replication of hepatitis C virus. *J. Gen. Virol.* **81**: 1631–1648.
- 2) Bartosch, B., Dubuisson, J., and Cosset, F.L. 2003. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. *J. Exp. Med.* **197**: 633–642.
- 3) Buonocore, L., Blight, K.J., Rice, C.M., and Rose, J.K. 2002. Characterization of vesicular stomatitis virus recombinants that express and incorporate high levels of hepatitis C virus glycoproteins. *J. Virol.* **76**: 6865–6872.
- 4) Cocquerel, L., Voisset, C., and Dubuisson, J. 2006. Hepatitis C virus entry: potential receptors and their biological functions. *J. Gen. Virol.* **87**: 1075–1084.
- 5) Farnaud, S., and Evans, R.W. 2003. Lactoferrin—a multifunctional protein with antimicrobial properties. *Mol. Immunol.* **40**: 395–405.
- 6) Feld, J.J., and Hoofnagle, J.H. 2005. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. *Nature* **436**: 967–972.
- 7) Hijikata, M., Kato, N., Ootsuyama, Y., Nakagawa, M., and Shimotohno, K. 1991. Gene mapping of the putative structural region of the hepatitis C virus genome by *in vitro* processing analysis. *Proc. Natl. Acad. Sci. U.S.A.* **88**: 5547–5551.
- 8) Hijikata, M., Mizushima, H., Tanji, Y., Komoda, Y., Hirowatari, Y., Akagi, T., Kato, N., Kimura, K., and Shimotohno, K. 1993. Proteolytic processing and membrane association of putative nonstructural proteins of hepatitis C virus. *Proc. Natl. Acad. Sci. U.S.A.* **90**: 10773–10777.
- 9) Hsu, M., Zhang, J., Flint, M., Logvinoff, C., Cheng-Mayer, C., Rice, C.M., and McKeating, J.A. 2003. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. *Proc. Natl. Acad. Sci. U.S.A.* **100**: 7271–7276.
- 10) Ikeda, M., Nozaki, A., Sugiyama, K., Tanaka, T., Naganuma, A., Tanaka, K., Sekihara, H., Shimotohno, K., Saito, M., and Kato, N. 2000. Characterization of antiviral activity of lactoferrin against hepatitis C virus infection in human cultured cells. *Virus Res.* **66**: 51–63.
- 11) Ikeda, M., Sugiyama, K., Mizutani, T., Tanaka, T., Tanaka, K., Sekihara, H., Shimotohno, K., and Kato, N. 1998. Human hepatocyte clonal cell lines that support persistent replication of hepatitis C virus. *Virus Res.* **56**: 157–167.
- 12) Ikeda, M., Sugiyama, K., Tanaka, T., Tanaka, K., Sekihara, H., Shimotohno, K., and Kato, N. 1998. Lactoferrin markedly inhibits hepatitis C virus infection in cultured human hepatocytes. *Biochem. Biophys. Res. Commun.* **245**: 549–553.
- 13) Inudoh, M., Kato, N., and Tanaka, Y. 1998. New monoclonal antibodies against a recombinant second envelope protein of hepatitis C virus. *Microbiol. Immunol.* **42**: 875–877.
- 14) Inudoh, M., Nyunoya, H., Tanaka, T., Hijikata, M., Kato, N., and Shimotohno, K. 1996. Antigenicity of hepatitis C virus envelope proteins expressed in Chinese hamster ovary cells. *Vaccine* **14**: 1590–1596.
- 15) Ishii, K., Takamura, N., Shimohara, M., Wakui, N., Shin, H.,

- Sumino, Y., Ohmoto, Y., Teraguchi, S., and Yamauchi, K. 2003. Long-term follow-up of chronic hepatitis C patients treated with oral lactoferrin for 12 months. *Hepatol. Res.* **25**: 226–233.
- 16) Iwasa, M., Kaito, M., Ikoma, J., Takeo, M., Imoto, I., Adachi, Y., Yamauchi, K., Koizumi, R., and Teraguchi, S. 2002. Lactoferrin inhibits hepatitis C virus viremia in chronic hepatitis C patients with high viral loads and HCV genotype 1b. *Am. J. Gastroenterol.* **97**: 766–767.
 - 17) Kato, N. 2001. Molecular virology of hepatitis C virus. *Acta Med. Okayama* **55**: 133–159.
 - 18) Kato, N., Hijikata, M., Ootsuyama, Y., Nakagawa, M., Ohkoshi, S., Sugimura, T., and Shimotohno, K. 1990. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. *Proc. Natl. Acad. Sci. U.S.A.* **87**: 9524–9528.
 - 19) Kato, N., Ikeda, M., Sugiyama, K., Mizutani, T., Tanaka, T., and Shimotohno, K. 1998. Hepatitis C virus population dynamics in human lymphocytes and hepatocytes infected *in vitro*. *J. Gen. Virol.* **79**: 1859–1869.
 - 20) Kato, N., and Shimotohno, K. 2000. Systems to culture hepatitis C virus. *Curr. Top. Microbiol. Immunol.* **242**: 261–278.
 - 21) Levay, P.F., and Viljoen, M. 1995. Lactoferrin: a general review. *Haematologica* **80**: 252–267.
 - 22) Lonnerdal, B., and Iyer, S. 1995. Lactoferrin: molecular structure and biological function. *Annu. Rev. Nutr.* **15**: 93–110.
 - 23) Matsuura, Y., Tani, H., Suzuki, K., Kimura-Someya, T., Suzuki, R., Aizaki, H., Ishii, K., Moriishi, K., Robison, C.S., Whitt, M.A., and Miyamura, T. 2001. Characterization of pseudotype VSV possessing HCV envelope proteins. *Virology* **286**: 263–275.
 - 24) Noguchi, M., and Hirohashi, S. 1996. Cell lines from non-neoplastic liver and hepatocellular carcinoma tissue from a single patient. *In Vitro Cell. Dev. Biol. Anim.* **32**: 135–137.
 - 25) Nozaki, A., Ikeda, M., Naganuma, A., Nakamura, T., Inudoh, M., Tanaka, K., and Kato, N. 2003. Identification of a lactoferrin-derived peptide possessing binding activity to hepatitis C virus E2 envelope protein. *J. Biol. Chem.* **278**: 10162–10173.
 - 26) Nozaki, A., and Kato, N. 2002. Quantitative method of intracellular hepatitis C virus RNA using LightCycler PCR. *Acta Med. Okayama* **56**: 107–110.
 - 27) Okada, S., Tanaka, K., Sato, T., Ueno, H., Saito, S., Okusaka, T., Sato, K., Yamamoto, S., and Kakizoe, T. 2002. Dose-response trial of lactoferrin in patients with chronic hepatitis C. *Jpn. J. Cancer Res.* **93**: 1063–1069.
 - 28) Saito, I., Miyamura, T., Ohbayashi, A., Harada, H., Katayama, T., Kikuchi, S., Watanabe, Y., Koi, S., Onji, M., Ohta, Y., Choo, Q.L., Houghton, M., and Kuo, G. 1990. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. *Proc. Natl. Acad. Sci. U.S.A.* **87**: 6547–6549.
 - 29) Tamura, T., Nozaki, A., Abe, K., Dansako, H., Naka, K., Ikeda, M., Tanaka, K., and Kato, N. 2005. cDNA microarray analysis of lactoferrin expression in non-neoplastic human hepatocyte PH5CH8 cells. *Biochim. Biophys. Acta* **1721**: 73–80.
 - 30) Tamura, K., Oue, A., Tanaka, A., Shimizu, N., Takagi, H., Kato, N., Morikawa, A., and Hoshino, H. 2005. Efficient formation of vesicular stomatitis virus pseudotypes bearing the native forms of hepatitis C virus envelope proteins detected after sonication. *Microbes Infect.* **7**: 29–40.
 - 31) Tanaka, K., Ikeda, M., Nozaki, A., Kato, N., Tsuda, H., Saito, S., and Sekihara, H. 1999. Lactoferrin inhibits hepatitis C virus viremia in patients with chronic hepatitis C: a pilot study. *Jpn. J. Cancer Res.* **90**: 367–371.
 - 32) Thomas, D.L. 2000. Hepatitis C epidemiology. *Curr. Top. Microbiol. Immunol.* **242**: 25–41.
 - 33) van der Strate, B.W., Beljaars, L., Molema, G., Harmsen, M.C., and Meijer, D.K. 2001. Antiviral activities of lactoferrin. *Antiviral Res.* **52**: 225–239.
 - 34) Yi, M., Kaneko, S., Yu, D.Y., and Murakami, S. 1997. Hepatitis C virus envelope proteins bind lactoferrin. *J. Virol.* **71**: 5997–6002.